HarringtonineCAS# 26833-85-2 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 26833-85-2 | SDF | Download SDF |
| PubChem ID | 276389 | Appearance | Powder |
| Formula | C28H37NO9 | M.Wt | 531.6 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (188.11 mM) *"≥" means soluble, but saturation unknown. | ||
| SMILES | CC(C)(CCC(CC(=O)OC)(C(=O)OC1C2C3=CC4=C(C=C3CCN5C2(CCC5)C=C1OC)OCO4)O)O | ||
| Standard InChIKey | HAVJATCHLFRDHY-KSZYUSJVSA-N | ||
| Standard InChI | InChI=1S/C28H37NO9/c1-26(2,32)8-9-28(33,15-22(30)35-4)25(31)38-24-21(34-3)14-27-7-5-10-29(27)11-6-17-12-19-20(37-16-36-19)13-18(17)23(24)27/h12-14,23-24,32-33H,5-11,15-16H2,1-4H3/t23-,24-,27+,28-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Harringtonine , an anticancer drug with high chemotherapeutic efficiency to human chronic granulocytic/myelomonocytic leukemia, has been reported to rapidly induce apoptosis in HL-60 cells in a wide scope/range of dosage by investigators from our lab and others. Harringtonine exerts its antiviral effects by inhibiting Chikungunya virus (CHIKV) viral protein synthesis. |
| Targets | Calcium Channel | Antifection |
| In vitro | Intracellular calcium distribution in apoptosis of HL-60 cells induced by harringtonine: intranuclear accumulation and regionalization.[Pubmed: 9619866]Cancer Lett. 1998 May 15;127(1-2):113-21.Harringtonine (HT), an anticancer drug with high chemotherapeutic efficiency to human chronic granulocytic/myelomonocytic leukemia, has been reported to rapidly induce apoptosis in HL-60 cells in a wide scope/range of dosage by investigators from our lab and others. Inhibition of Chikungunya Virus Replication by Harringtonine, a Novel Antiviral That Suppresses Viral Protein Expression[Reference: WebLink]Antimicrob. Agents Chemother., 2013, 57(1): 155-67.Chikungunya virus (CHIKV) is a mosquito-transmitted virus that has reemerged as a significant public health threat in the last decade. |
Harringtonine Dilution Calculator
Harringtonine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8811 mL | 9.4056 mL | 18.8111 mL | 37.6223 mL | 47.0278 mL |
| 5 mM | 0.3762 mL | 1.8811 mL | 3.7622 mL | 7.5245 mL | 9.4056 mL |
| 10 mM | 0.1881 mL | 0.9406 mL | 1.8811 mL | 3.7622 mL | 4.7028 mL |
| 50 mM | 0.0376 mL | 0.1881 mL | 0.3762 mL | 0.7524 mL | 0.9406 mL |
| 100 mM | 0.0188 mL | 0.0941 mL | 0.1881 mL | 0.3762 mL | 0.4703 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Harringtonine, a natural Cephalotaxus alkaloid, is an inhibitor of protein synthesis.
In Vitro:Harringtonine inhibits the elongation phase of translation by preventing substrate binding to the acceptor site on the 60-S ribosome subunit and therefore block aminoacyl-tRNA binding and peptide bond formation[1]. Harringtonine displays potent inhibition of Chikungunya virus infection with an EC50 of 0.24 μM. Harringtonine could inhibit other alphaviruses[2]. Harringtonine inhibits the growth of human myeloid leukemia cells in vitro at low concentrations. The mechanism of the antitumor action of harringtonine is considered to be an effect on protein synthesis and is characterized by breakdown of polysomes to monosomes[3].
References:
[1]. Fresno M, et al. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977 Jan;72(2):323-30.
[2]. Kaur P, et al. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother. 2013 Jan;57(1):155-67.
[3]. Piao YF, et al. Growth inhibition of human myeloid leukemia cells in vitro by harringtonine. Gan To Kagaku Ryoho. 1990 Feb;17(2):281-5.
- Coronalolic acid
Catalog No.:BCN5153
CAS No.:268214-52-4
- Coronalolide
Catalog No.:BCN5152
CAS No.:268214-51-3
- Coronalolide methyl ester
Catalog No.:BCN5151
CAS No.:268214-50-2
- Udenafil
Catalog No.:BCC5213
CAS No.:268203-93-6
- Debilon
Catalog No.:BCN7696
CAS No.:26808-51-5
- Indapamide
Catalog No.:BCC4788
CAS No.:26807-65-8
- Dehydrodiisoeugenol
Catalog No.:BCN1240
CAS No.:2680-81-1
- Xanthatin
Catalog No.:BCN5150
CAS No.:26791-73-1
- Robtein
Catalog No.:BCN4658
CAS No.:2679-65-4
- Amoxicillin
Catalog No.:BCC4625
CAS No.:26787-78-0
- Alibendol
Catalog No.:BCC4758
CAS No.:26750-81-2
- Perivine
Catalog No.:BCN2583
CAS No.:2673-40-7
- Homoharringtonine
Catalog No.:BCN4958
CAS No.:26833-87-4
- Triptohypol F
Catalog No.:BCN5154
CAS No.:268541-26-0
- Penfluridol
Catalog No.:BCC4696
CAS No.:26864-56-2
- 1,3-Bis[2-(4-aminophenyl)-2-propyl]benzene
Catalog No.:BCC8419
CAS No.:2687-27-6
- Isomahanimbine
Catalog No.:BCN3175
CAS No.:26871-46-5
- 6-Hydroxybenzofuran-2(3H)-one
Catalog No.:BCN5155
CAS No.:2688-49-5
- Oxysophocarpine
Catalog No.:BCN5156
CAS No.:26904-64-3
- 2(-4-Chloro-3-hydroxy-1-butynyl)-5-1,(3-pentadiynyl)thiophene
Catalog No.:BCN1465
CAS No.:26905-70-4
- Etravirine (TMC125)
Catalog No.:BCC5027
CAS No.:269055-15-4
- Fmoc-Orn(Dde)-OH
Catalog No.:BCC3534
CAS No.:269062-80-8
- H-D-Dab-OH.2HCl
Catalog No.:BCC3185
CAS No.:26908-94-1
- Timolol Maleate
Catalog No.:BCC4340
CAS No.:26921-17-5
Intracellular calcium distribution in apoptosis of HL-60 cells induced by harringtonine: intranuclear accumulation and regionalization.[Pubmed:9619866]
Cancer Lett. 1998 May 15;127(1-2):113-21.
Harringtonine (HT), an anticancer drug with high chemotherapeutic efficiency to human chronic granulocytic/myelomonocytic leukemia, has been reported to rapidly induce apoptosis in HL-60 cells in a wide scope/range of dosage by investigators from our lab and others. In the present studies, by using video enhancement contrast (VEC) microscopy, we dynamically analyzed changes in intracellular calcium distribution in a single HL-60 cell over the period from the initiation of apoptosis to the obvious appearance of chromatin condensation. The results from this paper demonstrated the striking distinction of intracellular calcium distribution at different time points after treatment with HT. Before treatment in normal HL-60 cells the highest [Ca2+]i accumulation was observed in the peri-nuclear area and the lowest was observed in the nucleus; after treatment with 1 microg/ml HT for 30 min intracellular calcium diffused all over the cell compartments, while intranuclear calcium increased comparatively and significantly. The phenomenon of intranuclear calcium accumulation was further confirmed by using laser scanning confocal microscopy (LSCM). In addition, co-localization of the highest calcium region with condensed chromatin in apoptotic HL-60 cells was also observed by LSCM. Our results suggest that two sequential alterations of intracellular calcium distribution occurred in apoptotic HL-60 cells induced by HT, i.e. (a) accumulation of calcium in the nucleus and (b) regionalization in a specific nuclear region.
